Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biogen
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
gene therapy
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
novartis
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
zolgensma
3
×
abbvie
bristol-myers squibb
eli lilly
fda
glaxosmithkline
johnson & johnson
microbiome
migraine
What
bio
3
×
roundup
news
america
approval
august
biogen
biogen’s
biopharmaceutical
biotech
busy
companies
continues
convo
convoluted
days
decisions
democrats
devices
dreams
drug
drugs
earlier
failures
fda
head
headaches
healthcare
holding
insurance
ipo
legacy
littered
moves
nash
new
nods
opioid
past
previews
Language
unset
Current search:
zolgensma
×
bio
×
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
4 years ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com
4 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
